Incretin mimetics are a class of drugs used to Type 2 diabetes. Recent studies have shown that incretin mimetics are linked with pancreatic cancer. In 2013, the FDA released unpublished academic research that demonstrated pre-cancerous cellular changes known as pancreatic duct metaplasia in Type 2 diabetic patients treated with incretin mimetics.
Incretin mimetics act like incretin hormones and stimulate glucose dependent insulin release, acting as antihyperglycemics.
Drugs that are in this class include:
- Byetta and Bydureon (exenatide)
- Bydureon (exenatide)
- Januvia, Janumet, Janumet XR, and Juvisync (sitagliptin)
- Janumet (sitagliptin)
- Victoza and Saxenda (liraglutide)
- Onglyza and Kombiglyze XR (saxagliptin)
- Nesina, Kazano, and Oseni (Alogliptin)
- Tradjenta and Jentadueto (Linagliptin)
If you’ve taken one of these drugs and have experienced pancreatic issues, the drug company may be liable for your injury. Fill out the form below, and an attorney will assess your case.
[wpforms id=”74855″ title=”false” description=”false”]
One thought on “Incretin Mimetics and pancreatic complications”
Is there any Type II Diabetes medications that do not cause something horrible, besides the weight gain?